Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Innate Pharma (IPHA) over the last 5 years, with Q2 2025 value amounting to 1.5%.

  • Innate Pharma's Return on Capital Employed fell 7900.0% to 1.5% in Q2 2025 from the same period last year, while for Jun 2025 it was 1.5%, marking a year-over-year decrease of 7900.0%. This contributed to the annual value of 0.47% for FY2024, which is 3800.0% down from last year.
  • Latest data reveals that Innate Pharma reported Return on Capital Employed of 1.5% as of Q2 2025, which was down 7900.0% from 0.85% recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Return on Capital Employed ranged from a high of 0.35% in Q4 2021 and a low of 1.5% during Q2 2025
  • Its 5-year average for Return on Capital Employed is 0.76%, with a median of 0.71% in 2024.
  • Per our database at Business Quant, Innate Pharma's Return on Capital Employed plummeted by -1000bps in 2024 and then crashed by -7900bps in 2025.
  • Quarter analysis of 5 years shows Innate Pharma's Return on Capital Employed stood at 0.35% in 2021, then tumbled by -53bps to 0.53% in 2022, then tumbled by -42bps to 0.75% in 2023, then dropped by -14bps to 0.85% in 2024, then plummeted by -77bps to 1.5% in 2025.
  • Its last three reported values are 1.5% in Q2 2025, 0.85% for Q4 2024, and 0.71% during Q2 2024.